Call Us Contact Us
+44 1494 818 000     Online Enquiry
Lines open
Monday to Thursday
08:30 to 18:00
Friday
08:30 to 17:30
Pharmaceutical | Medical Devices | Scientific | Consumer Healthcare | Dental | Animal Health | FMCG | Executive
         
Latest Jobs
Exclusive vacancies may not be shown here, please contact on +44 or for more information.
Have you registered?
Once you register you can see additional job details, save jobs, track your applications and manage e-lert preferences.

Register now
Testimonials
I have had a different experience dealing with Zenopa, and feel without the support I may not have had the critical edge in the assessment centre.
Showab, 2012

GlaxoSmithKline seeking marketing authorisation for Arzerra

6 February 2009 00:00 in Pharmaceutical Company Product News


GlaxoSmithKline (GSK) and Genmab are seeking European marketing authorisation for Arzerra, according to the former.

Used for the treatment of chronic lymphocytic leukaemia, the product targets a binding site on the CD30 molecule of B-cells.

The application to the European Union follows a submission to the US Food and Drug Administration on January 30th this year.

Carlo Russo, senior vice-president of GSK's BioPharm subsidiary, said the product is a "new generation of monoclonal antibody".

He went on to note: "We plan additional studies to understand its potential in lymphomas and selected autoimmune diseases."

Chief executive officer of Genmab Lisa Drakeman went added the collaboration is studying the drug's efficacy as a treatment for other conditions.

Last month, GSK's Synflorix therapy received positive opinion in Europe.

The paediatric vaccine is set to be used as a protective treatment against invasive pneumococcal disease and middle ear infections, which are caused by Streptococcus pneumoniae.

Other news stories from 06/02/2009

Related news

Read more in the Zenopa News Archive

How this news is generated

Story collated for Zenopa by the Adfero News Agency



   
© Copyright 2013 Zenopa Ltd